TW EN

scroll

Go Top

Overview

TCTC

1. Urothelial carcinoma (UC) and prostate cancer (PC) are the most common malignancy of the urinary system. The incidence is rising gradually due to the growing number of elderly people. The upper tract UC (UTUC) arising from renal pelvis and ureter accounts for only 5~10% of all UCs; however, the incidence of UTUC markedly increases to 40% of the UCs in Taiwan.

2. Assist pharmaceutical company to conduct clinical trial of new drug.

3. Conduct PI-initiated clinical trial.

4. Participate in international multi-center institution clinical trial.

5. Through TCTCGU, propose clinical trial to pharmaceutical company

6. Identify new biomarkers of UC and PC

7. Assist patients to find proper therapy strategy

Strengths

TCTC

1. Urothelial carcinoma

2. Prostate cancer

3. Renal cell carcinoma

4. Cooperation with pharmaceutical company to conduct clinical trial

5. Participate in international pharmaceutical company clinical trial

Major Achievements

TCTC

Clinical trial

International cooperation

  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
  • Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
  • Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial All drugs have been approved by FDA/TFDA.
 

Society aspect

  • Combined biotechnology research of our consortium and other company research center
  • Give suggestion of our clinical application view to company
  • Offer clinical trial service before marketing
  • Assist to evaluate new drug and medical device safety, efficacy
  • To promote potential new drug and medical device marketing to benefit people
 

Members

TCTC

Department of Urology, Kaohsiung Medical University Hospital

Department of Urology, Kaohsiung Medical University Hospital

Department of Urology, Kaohsiung Medical University Hospital

Department of Urology, Kaohsiung Medical University Hospital

Department of Urology, Kaohsiung Medical University Hospital

Department of Urology, Kaohsiung Medical University Hospital

Department of Urology, National Taiwan University Hospital

Department of Urology, National Taiwan University Hospital

Department of Urology, Taichung Veterans General Hospital

Department of Urology, Taichung Veterans General Hospital

Department of Urology, Taichung Veterans General Hospital

Department of Urology, Taichung Veterans General Hospital

Department of Urology, National Cheng Kung University Hospital

Department of Urology, National Cheng Kung University Hospital

Department of Urology, Taipei Veterans General Hospital

Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou

Department of Urology, China Medical University Hospital

Contact Information

c-IRB

Wei-Ming Li

Email:u8401067@yahoo.com.tw

TEL: ext